


Rad226a - Lecture #17

Research topics in ^{13}C MRS


- Neurotransmission
- ^{13}C MRS
- Hyperpolarized ^{13}C MRS
- References
 - Rothman, et al., “ ^{13}C MRS studies of neuroenergetics and neurotransmitter cycling in humans”, NMR Biomedicine, 2011 Oct;24(8):943-57.
 - Hurd et al., “Hyperpolarized ^{13}C Metabolic Imaging Using Dissolution Dynamic Nuclear Polarization”, JMR 36:1314–1328 (2012) .

Neurons and Neurotransmission

- Neurons carry action potentials, but are not directly connected.
- Axon-dendrite connections rely on chemicals (neurotransmitters).
- Neurotransmitters can be excitatory or inhibitory.





Glutamate is the major excitatory neurotransmitter in the human brain with >80% of synapses utilizing glutamate. **Thomas C. Südhof**
Stanford University




The Nobel Prize in Physiology
or Medicine 2013

The brain in more than just neurons..



Energy metabolism is coupled with neurotransmission.

Neurotransmitter Cycling



Excitatory


Neuron energy cycle

Astroglial energy cycle

Glutamate-Glutamine cycle




Rothman, et al, NMR Biomedicine, 2011.

Probing Brain Function with Carbon




Probing Brain Function with ^{13}C MRS




Infuse ^{13}C -glucose
(or ^{13}C -acetate)



Collect spectra



Quantify spectra
over time





$V_{\text{TCA}n}$ = neuron TCA flux

$V_{\text{TCA}g}$ = glial TCA flux

V_{NT} = Glu/Gln neurotransmitter flux

Metabolic Modeling




$$\begin{aligned} \frac{dGlu_4}{dt} &= \frac{L_3}{L} Vgly + \frac{Gln_4}{Gln} Vcycle + (0)Vdil \\ &\quad - \frac{Glu_4}{Gln} (Vtca + Vgln), \\ \frac{dGln_4}{dt} &= \frac{Glu_4}{Gln} Vgln - \frac{Gln_4}{Gln} (Vcycle + Vefflux), \\ \frac{dGlu_3}{dt} &= \frac{1}{2} \frac{L_3}{L} Vana + \frac{1}{2} (0)Vana + \frac{1}{2} \frac{Glu_4}{Glu} Vtca_{net} \\ &\quad + \frac{1}{2} \frac{Glu_3}{Glu} Vtca_{net} + \frac{Gln_3}{Gln} Vcycle \\ &\quad - \frac{Glu_3}{Glu} (Vtca + Vgln), \\ \frac{dGln_3}{dt} &= \frac{Glu_3}{Gln} Vgln - \frac{Gln_3}{Gln} (Vcycle + Vefflux), \\ \frac{dGlu_{3,4}}{dt} &= \frac{L_3}{L} \frac{Glu_3}{Glu} Vtca + \frac{Gln_{3,4}}{Gln} Vcycle \\ &\quad - \frac{Glu_{3,4}}{Glu} (Vtca + Vgln), \\ \frac{dGln_{3,4}}{dt} &= \frac{Glu_{3,4}}{Glu} Vgln - \frac{Gln_{3,4}}{Gln} (Vcycle + Vefflux). \end{aligned}$$



NV_{TCA} , rate of neuronal TCA cycle
 AV_{TCA} , rate of astroglial TCA cycle
 V_{cycle} , rate of Glu-Gln cycle;

Probing Brain Function with ^{13}C MRS

Glutamate



Glutamine




~45 cc, 10 min acq

~10 cc, 10 min acq

^{13}C and ^1H spectra from human visual cortex during an infusion of $[1-^{13}\text{C}]$ glucose.

Hardware




Multinuclear Pulse Sequences

Direct Detection

For in vivo ^{13}C -infusion brain studies (e.g. labeled glucose or acetate) ...

- ^{13}C spectrum: low sensitivity, excellent peak discrimination.
- Simple ^{13}C excitation and detection is rarely used do to poor sensitivity
- Polarization transfer is commonly used: INEPT, DEPT
- Almost all methods use decoupling.



4T ^{13}C spectrum obtained from a 45 ml volume in the human visual cortex during an infusion of 67%-enriched $[1-^{13}\text{C}]$ glucose. (DEPT sequence).

Polarization Transfer

- MRI sensitivity given by


$$SNR \propto \frac{\overset{\text{polarization}}{\left(\frac{\gamma\hbar B_0}{2kT}\right)} \overset{\text{magnetic moment}}{\left(\frac{\gamma\hbar}{2}\right)} \overset{\omega_0}{(\gamma B_0)}}{\underset{\text{noise}}{\gamma B_0}} = \frac{\gamma^2 \hbar^2 B_0}{4kT}$$

- In polarization transfer, we seek to exploit ^1H - ^{13}C J coupling to find a pulse sequence with sensitivity given by...

$$SNR \propto \frac{\overset{\text{"proton" polarization}}{\left(\frac{\gamma_H \hbar B_0}{2kT}\right)} \overset{\text{"carbon" detecton}}{\left(\frac{\gamma_C \hbar}{2}\right)} (\gamma_C B_0)}{\gamma_C B_0} = \frac{\gamma_H \gamma_C \hbar^2 B_0}{4kT}$$

- Given $\gamma_H \approx 4\gamma_C$, this will yield a 4x sensitivity increase!


Methods: INEPT



Human studies,
occipital lobe, 4T

A Key Result...

- Direct linkage between neuroenergetics and neurotransmitter flux
- 1:1 relationship between neuronal TCA and Glu/Gln cycling rates





Rat cortex

Applications

- ^{13}C MRS provides the only noninvasive measurements of neurotransmitter cycling and cell-specific neuroenergetics.
- Major contributions to understanding...
 - Metabolic coupling between neurons and glia.
 - High neuronal activity of resting brain.
 - Alternations in neurological and psychiatric disease.
- Pathologies include: depression, drug addiction, epilepsy, metabolic disorders, hepatic encephalopathy, and neurodegenerative disorders.

Example: Aging



Boumezbeur, et al, Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy JCBFM, (2010) 30, 211–21

Hyperpolarized ^{13}C MR

A Complementary Method to PET for Imaging In Vivo Metabolism




Daniel M. Spielman, Ph.D.
Dept. of Radiology
Stanford University
Email: spielman@stanford.edu

Lucas Center for Medical Imaging




PET/MR/¹³C Center for Metabolic Imaging



GE Spinlab

Cancer and the Warburg Effect



Metabolic Therapy Challenges


- Metabolic reprogramming represents a shifted balance towards glycolysis (GLY) from oxidative phosphorylation (OXPHOS)
- Malignant glioma are ideal candidates
 - Highly resistant to conventional treatments
 - Robustly manifest metabolic reprogramming
- Critical clinical obstacle: robust measurement of response

$$\text{Proposed metric: Metabolic therapy index} = \frac{[\text{Glycolysis}]}{[\text{OXPHOS}]}$$

How can we measure GLY/OXPHOS in vivo?


Hyperpolarized ^{13}C MRS

Hypothesis: Imaging of hyperpolarized $[1-^{13}\text{C}]$ pyruvate can provide one such metabolic therapy index.



PET vs Hyperpolarized ^{13}C MRS

- Key idea: inject a “magnetically” enhanced biological substrate and image both the substrate and its downstream metabolic products.



Key technology: A polarizer that magnetically prepares the substrate to boost its MR visibility by $>10,000$ fold.

MR Sensitivity

- Thermal equilibrium magnetization:

$$M_0 = \rho \frac{\gamma^2 \hbar^2 B_0}{4kT} = \rho \left(\frac{\gamma \hbar}{2} \right) \left(\frac{\gamma \hbar B_0}{2kT} \right)$$

↑
Magnetic
Polarization
 $P = \frac{N^+ - N^-}{N^+ + N^-}$

Spins/unit
moment
volume


- Increasing sensitivity

- Increase ρ (*e.g.* isotopically enriched ^{13}C substrates vs natural abundance)
- Increase polarization:
 - Higher B_0
 - Lower T
 - Change “effective” γ ?!?

In vivo hyperpolarized ^{13}C via DNP exploits all of these effects!

Hyperpolarization


- Hyperpolarization: creating nuclear spin polarization much greater than that achieved at normal thermal equilibrium.



MR signal proportional to population difference!


Hyperpolarization

- Increases net nuclear magnetization
- Does **NOT** change chemical properties.



Brute Force

Boltzmann distribution at 3T



Dissolution DNP

Step 1: Polarization (~2 hrs)

- ^{13}C -labeled substrate + free radical
- 5T magnet, 1K temperature, 20 mM microwave



Step 2: Dissolution (~30 s)

- Water is heated and pressurized
- Melts the sample and fills the syringe
- Quality control checks before syringe is released



Inject and image before signal disappears (~ 3 min)!



40% polarization ~ 50,000 fold
signal gain!

In vivo $T_1 = 40$ s

In Vivo Imaging Requirements


- Low toxicity (mM conc.)
- Long NMR relaxation times
- Chemical shift separation
- Rapid cellular uptake
- Rapid metabolism

Signal decays by relaxation and dilution









➔ Focus on low molecular weight endogenous compounds.

Example: [1-¹³C]pyruvate



25% polarization ~ 30,000 fold signal gain!
In vivo $T_1 = 30$ s

Hyperpolarized [1-¹³C]Pyruvate



C6 rat glioma model

Hyperpolarized [1-¹³C]Pyr imaging


Proposed metric: Metabolic therapy index = $\frac{[^{13}\text{C-Lactate}]}{[^{13}\text{C-Bic}]}$

Hyperpolarized ^{13}C Lactate, Pyruvate, and Alanine: Noninvasive Biomarkers for Prostate Cancer Detection and Grading

Mark J. Albers,^{1,2} Robert Bok,² Albert P. Chen,² Charles H. Cunningham,³ Matt L. Zierhut,^{1,2} Vickie Yi Zhang,² Susan J. Kohler,⁴ James Tropp,⁵ Ralph E. Hurd,⁵ Yi-Fen Yen,⁵ Sarah J. Nelson,^{1,2} Daniel B. Vigneron,^{1,2} and John Kurhanewicz^{1,2}

¹Department of Bioengineering, University of California San Francisco and University of California Berkeley; ²Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; ³Sunny Brook Health Sciences Centre, Toronto, Ontario, Canada; ⁴Union College, Schenectady, New York; and ⁵GE Healthcare, Menlo Park, California

First clinical trial of hyperpolarized [1- ^{13}C]Pyr completed in 2012.





Cardiac Metabolism Measured Noninvasively by Hyperpolarized ^{13}C MRI






Klaes Golman,¹ J. Stefan Petersson,^{1*} Peter Magnusson,¹ Edvin Johansson,¹ Per Åkeson,² Chun-Ming Chai,³ Georg Hansson,¹ and Sven Månsson³

Pig Coronary Occlusion Model





Proton

Perfusion Delayed enhancement Alanine

Bicarb



15 min occlusion (stunned) + 2 hrs reperfusion



45 min occlusion (infarcted) + 2 hrs reperfusion


PET + Hyperpolarized ^{13}C

- Opportunity: currently only two Spinlab systems installed adjacent to PET/MR scanners.

- ^{18}F -FDG and ^{13}C -pyruvate




- Measures glucose metabolic pathway at multiple points: uptake vs. glycolysis/oxidative phosphorylation balance
- Tumors hot on FDG: initial studies (animals) show elevated ^{13}C Lac labeling
- Tumors cold on FDG: hyp ^{13}C -pyr ?
- Inflammation: FDG vs. hyp ^{13}C -pyr ?

- Other tracers/substrates




PET + Hyperpolarized ^{13}C

Rat ENU tumor model




Are there synergies to exploit with simultaneous PET/HP ^{13}C ?

Cancer and the Warburg Effect



Will reversing the Warburg Effect slow tumor growth?

Rat C6 Glioma Bevacizumab Study




Decreased Lac/Bic ratio predicts survival

Note: no correlations found with respect to tumor size.

Clinical Hyperpolarized ^{13}C Studies

- FDA IND ##135767–“Hyperpolarized [1- ^{13}C]Pyruvate Injection”,
- Stanford IRB, protocol #39845–“A Pilot Study to Assess Lactate and Bicarbonate Detection within Malignant Brain Tumors Using [1- ^{13}C]-pyruvate DNP Magnetic Resonance Spectroscopy (MRS)”.

Step 1:
Pharmacy kit
preparation
24 hrs prior
to injection



Lucas Center Radiochemistry Cleanroom

Step 2:
Polarization
2.5-3 hrs prior
to injection



Polarizer
~ 3 hrs



MR scanner
~ 2-3 min scan



MEDRAD
power
injector

Step 4:
Pyr injection
and MRI scan
2-3 min



Fast filter
test

Parameter	High Acceptance Criteria	Low
280 mM ±	100 mM	≥ 220 mM
8.5 pH ±	7.2 pH	≥ 6.5 pH
3.0 μM ±	0.9 μM	
40°C ±	37°C	≥ 25°C
90s ±	77 sec	
	~ 40 mL	
	≥ 27%	

Step 3:
Dissolution and
quality control
checks
~90s prior to
injection

Recruitment - volunteers



Volunteers wanted for a pyruvate tracer Research Study



Looking for healthy volunteers

We are conducting a research study to assess the safety of infusing ^{13}C -labeled hyperpolarized pyruvate (HP-pyruvate) prior to performing magnetic resonance imaging (MRI)

The study requires 3 visits:

Visit 1: Review and sign consent form, medical history review, vital signs, ECG, and blood draw (Approximately 2 hrs)

Visit 2: MRI using HP-pyruvate and observation (Approximately 2 hrs)

3-5 hours later: Vital signs and ECG (Approximately 30 mins)

Visit 3: Follow up visit or telephone call (Approximately 30 mins)

Participants will receive financial compensation for their time spent in this research study. There will be no direct benefits to you from participating in this study, but the knowledge gained from this study may help future cancer patients.

Key eligibility requirements:

- Must be 18 years old or older
- Must not be undergoing active treatment for malignancy
- No history of allergic reactions to MRI contrast (gadolinium)
- Must be able to undergo an MRI
- Volunteers cannot be pregnant or nursing.
- Please note that this is an abbreviated list of study requirements.

If you are interested, please contact the research nurse below for more information


Stephanie Lewis, RN, MSN

Email: lewisste@stanford.edu


Tel: (650) 723-0381

First Stanford Human Hyperpolarized ^{13}C Results

Subject 1




Subject 2




BPM31510 Phase II GBM Trial

Trial as planned



Proposed modification with HP ¹³C-pyruvate



Next lecture: Brain metabolic
changes during heart/lung
bypass surgery